Expression of ZNF711 gene in ovarian cancer and its prognostic value
10.3760/cma.j.cn115355-20231020-00154
- VernacularTitle:卵巢癌ZNF711基因的表达及其预后价值
- Author:
Li ZHANG
1
;
Yixuan WANG
1
;
Shaohua ZHANG
1
;
Zanhong WANG
1
Author Information
1. 山西白求恩医院 山西医学科学院 同济山西医院 山西医科大学第三医院妇产科，太原 030032
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
ZNF711 protein;
Tumor microenvironment;
Immunocyte;
Prognosis
- From:
Cancer Research and Clinic
2025;37(3):211-217
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of ZNF711 in ovarian cancer and its relationship with prognosis and its possible role.Methods:A retrospective cohort study was conducted. The GEPIA database (data updated in October 2020) was used to analyze the expression of ZNF711 mRNA in 426 ovarian cancer samples and 88 normal ovarian tissue samples; 424 ovarian cancer patients were screened from the GEPIA database, and 373 ovarian cancer patients were screened from the Kaplan-Meier Plotter database. The patients were grouped according to the median relative expression levels of ZNF711 mRNA in ovarian cancer samples from the two databases, and the overall survival of the two groups in the same database was compared. The cBioPortal database (data updated in September 2023) was used to screen for the top 30 genes co-expressed with ZNF711 in ovarian cancer tissues from 489 ovarian serous cystadenoma samples in The Cancer Genome Atlas (TCGA) database; these 30 co-expressed genes were imported into the David database (data updated in October 2023) for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The correlation between ZNF711 expression and 6 types of immune cell infiltration in ovarian cancer was analyzed based on the TIMER database gene module. The ovarian cancer tissues from 178 ovarian cancer patients who underwent surgical treatment at Shanxi Bethune Hospital from January 2012 to December 2017, as well as the normal ovarian tissues from 53 patients who underwent total hysterectomy and bilateral adnexectomy for uterine fibroids during the same period were collected. Immunohistochemistry was used to detect the expression of ZNF711 protein in ovarian tissues. The immunohistochemical score was calculated by multiplying the positive cell ratio score and the staining intensity score, ranging from 0 to 12 points, and low or high expression of ZNF711 protein was determined by whether it was ≤ 8 points. The overall survival of patients with high and low expression of ZNF711 protein, as well as the distribution of patients with high and low expression of ZNF711 protein in different clinicopathological stratifications were compared; univariate and multivariate Cox proportional hazards models were used to analyze the influencing factors of overall survival in ovarian cancer patients.Results:Among 426 ovarian cancer tissue samples and 88 normal ovarian tissue samples in the GEPIA database, the relative expression level of ZNF711 mRNA in ovarian cancer tissues was lower than that in normal ovarian tissues, and the difference was statistically significant ( P < 0.05). The median relative expression levels of ZNF711 mRNA in ovarian cancer tissues were 8.46 and 8.57 in the GEPIA database and Kaplan-Meier Plotter database, respectively. The overall survival of the ZNF711 high expression group (212 cases) was better than that of the ZNF711 low expression group (212 cases) in the GEPIA database ( P = 0.010), and the overall survival of the ZNF711 high expression group (242 cases) was better than that of the ZNF711 low expression group (131 cases) in the Kaplan-Meier Plotter database ( P = 0.002). GO enrichment analysis of the top 30 ZNF711 co-expressed genes screened from ovarian cancer tissues in the cBioPortal database showed that these genes were mainly enriched in biological processes such as DNA-templated regulation of transcription, synapse assembly, regulation of transcription from RNA polymerase Ⅱ promoter, cell adhesion of calcium channels, etc. The involved cellular compositions were mainly enriched in the nucleus, ribonucleoprotein complex, etc. The involved molecular functions were mainly enriched in RNA polymerase Ⅱ core promoter proximal region sequence-specific DNA binding, protein binding, mRNA 3'UTR AU-rich region binding, etc. KEGG pathway analysis showed that the ZNF711 co-expressed genes were mainly enriched in processes such as herpes simplex virus type Ⅰ infection, osteoclast differentiation, antigen processing and presentation, Fc γ R-mediated phagocytosis, etc. Analysis using TIMER database found that the expression level of ZNF711 was negatively correlated with B cells, CD8 + T cells, neutrophils, and dendritic cells (all P < 0.05), but it was not correlated with CD4 + T cells or macrophages (both P > 0.05). The immunohistochemistry results of clinical specimens showed that the immunohistochemical scores of ZNF711 in 178 cases of ovarian cancer tissue and 53 cases of normal ovarian tissue were (3.0±1.6) points and (6.9±1.8) points, respectively, and the difference was statistically significant ( t = 14.42, P < 0.001); the overall survival of the ZNF711 low expression group (63 cases) was worse than that of the ZNF711 high expression group (115 cases) ( P = 0.008); there were statistically significant differences in the distribution of high and low expression of ZNF711 protein among ovarian cancer patients of different ages, International Federation of Obstetrics and Gynecology staging, R0 resection, differentiation degree, and ascites (all P = 0.001). The results of multivariate Cox regression analysis showed that non-R0 resection (non-R0 resection vs. R0 resection, HR = 15.862,95% CI: 4.440-56.661) and low expression of ZNF711 protein (high expression vs. low expression, HR = 0.421, 95% CI: 0.089-1.987) were independent risk factors for poor overall survival in ovarian cancer patients (both P < 0.05). Conclusions:ZNF711 is lowly expressed in ovarian cancer and is associated with poor prognosis of patients. It may be an important molecule involved in the progression of ovarian cancer.
